Dimensional Fund Advisors LP Grows Stock Holdings in Abbott Laboratories $ABT

Dimensional Fund Advisors LP grew its stake in shares of Abbott Laboratories (NYSE:ABT) by 1.9% during the third quarter, Holdings Channel reports. The firm owned 9,019,949 shares of the healthcare product maker’s stock after purchasing an additional 169,115 shares during the period. Dimensional Fund Advisors LP’s holdings in Abbott Laboratories were worth $1,208,086,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in ABT. Charles Schwab Trust Co lifted its holdings in shares of Abbott Laboratories by 109.8% in the third quarter. Charles Schwab Trust Co now owns 29,412 shares of the healthcare product maker’s stock worth $3,939,000 after buying an additional 15,394 shares in the last quarter. Asset Management One Co. Ltd. increased its holdings in Abbott Laboratories by 2.4% during the 3rd quarter. Asset Management One Co. Ltd. now owns 858,834 shares of the healthcare product maker’s stock worth $115,032,000 after acquiring an additional 19,966 shares during the period. Nordea Investment Management AB lifted its stake in Abbott Laboratories by 6.1% in the 3rd quarter. Nordea Investment Management AB now owns 329,430 shares of the healthcare product maker’s stock worth $43,785,000 after purchasing an additional 18,974 shares in the last quarter. AE Wealth Management LLC boosted its holdings in Abbott Laboratories by 20.8% in the 3rd quarter. AE Wealth Management LLC now owns 65,504 shares of the healthcare product maker’s stock valued at $8,774,000 after purchasing an additional 11,264 shares during the period. Finally, Mawer Investment Management Ltd. increased its holdings in shares of Abbott Laboratories by 5.9% in the third quarter. Mawer Investment Management Ltd. now owns 1,255,780 shares of the healthcare product maker’s stock worth $168,199,000 after purchasing an additional 70,122 shares during the period. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Trading Down 0.5%

ABT stock opened at $113.55 on Wednesday. The company has a market capitalization of $197.31 billion, a PE ratio of 30.52, a price-to-earnings-growth ratio of 1.82 and a beta of 0.74. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.18 and a current ratio of 1.58. Abbott Laboratories has a one year low of $105.27 and a one year high of $141.23. The company’s 50 day moving average price is $116.90 and its two-hundred day moving average price is $125.00.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, meeting the consensus estimate of $1.50. The company had revenue of $11.46 billion for the quarter, compared to analyst estimates of $11.80 billion. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.73%. The firm’s quarterly revenue was up 4.4% compared to the same quarter last year. During the same quarter last year, the firm earned $1.34 EPS. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. As a group, analysts predict that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be issued a dividend of $0.63 per share. The ex-dividend date is Wednesday, April 15th. This represents a $2.52 annualized dividend and a yield of 2.2%. Abbott Laboratories’s dividend payout ratio is currently 67.74%.

Insider Buying and Selling at Abbott Laboratories

In related news, VP John A. Jr. Mccoy sold 585 shares of the company’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $67,614.30. Following the completion of the sale, the vice president directly owned 24,628 shares in the company, valued at $2,846,504.24. This represents a 2.32% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, SVP Eric Shroff sold 709 shares of the firm’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $81,946.22. Following the completion of the sale, the senior vice president directly owned 39,164 shares in the company, valued at approximately $4,526,575.12. This trade represents a 1.78% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 3,055 shares of company stock worth $353,097 over the last quarter. Company insiders own 0.46% of the company’s stock.

Analyst Ratings Changes

ABT has been the subject of several research analyst reports. Barclays dropped their price objective on Abbott Laboratories from $169.00 to $142.00 and set an “overweight” rating for the company in a research note on Monday, February 2nd. BTIG Research cut their price objective on Abbott Laboratories from $145.00 to $140.00 and set a “buy” rating for the company in a report on Tuesday, February 17th. Citigroup lowered their target price on shares of Abbott Laboratories from $155.00 to $140.00 and set a “buy” rating on the stock in a research note on Friday, January 23rd. Freedom Capital raised shares of Abbott Laboratories from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 29th. Finally, The Goldman Sachs Group lowered their price objective on shares of Abbott Laboratories from $152.00 to $140.00 and set a “buy” rating on the stock in a research report on Friday, January 23rd. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $137.05.

More Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: FDA cleared Abbott’s redesigned CardioMEMS Hero remote heart‑failure monitor — a smaller, lighter reader intended to improve patient convenience and clinical workflow. The approval, together with existing reimbursement for implantable PA sensors, could boost physician adoption and revenue potential in Abbott’s cardiac portfolio. Abbott wins FDA approval for updated heart failure monitoring device How FDA Approval of CardioMEMS Hero Remote Monitor At Abbott (ABT) Has Changed Its Investment Story
• Neutral Sentiment: Analyst commentary highlights reasons to like Abbott’s durable device franchises and margin profile but reiterates skepticism after the recent softer quarter that contributed to underperformance versus the S&P over the past six months. This keeps sentiment mixed until revenue and growth re‑acceleration are clearer. 2 Reasons to Like ABT and 1 to Stay Skeptical
• Negative Sentiment: Clustered insider selling: multiple senior executives sold a combined ~3,055 shares on March 2 at about $115.58 per share (notable filings from VP John McCoy, EVPs Mary Moreland, Daniel Salvadori, Elizabeth Cushman and SVP Eric Shroff). While the executives retain large holdings, concentrated sales can pressure sentiment near the sale price. SEC Form 4 (John A. Jr. McCoy)
• Negative Sentiment: Market reaction/price momentum — coverage and market notes report ABT shares have recently pulled back (near the mid‑$110s) after the quarter, which is reinforcing selling pressure in the near term. Investors are watching upcoming catalysts and whether CardioMEMS adoption lifts growth enough to reverse the trend. Abbott (ABT) Stock Sinks As Market Gains: Here’s Why Abbott (ABT) Stock Sinks As Market Gains: Here’s Why (Zacks)

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.